REGN and SAN Related Headlines

Mar 18, 2023 10:00AM Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis

Jan 30, 2023 01:00AM Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis

Dec 21, 2022 05:29PM Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Dec 16, 2022 07:30AM Regeneron (REGN), Sanofi (SNY) Announces Dupixent Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis

Dec 16, 2022 07:29AM Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis

Dec 15, 2022 12:59AM Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis

REGN and SAN Related Press Releases

Mar 18, 2023 10:00AM Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis

Jan 30, 2023 01:00AM Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis

Dec 21, 2022 05:29PM Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Dec 16, 2022 07:29AM Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis

Dec 15, 2022 12:59AM Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis

REGN and SAN Related SEC Filings